 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- | CCI-001 / PharmaMatrix Holdings
Trial completion date, Trial primary completion date, Metastases: A Study of CCI-001 in Patients With Recurrent and/or Metastatic Solid Tumours (clinicaltrials.gov) - Apr 4, 2024
P1, N=70, Recruiting, Sponsor: PharmaMatrix Holdings Ltd
Trial completion date: May 2023 --> May 2025 | Trial primary completion date: May 2023 --> May 2025
- | CCI-001 / PharmaMatrix Holdings
Enrollment open, Metastases: A Study of CCI-001 in Patients With Recurrent and/or Metastatic Solid Tumours (clinicaltrials.gov) - Jul 28, 2021
P1, N=70, Recruiting, Sponsor: PharmaMatrix Holdings Ltd
Trial completion date: May 2023 --> May 2025 | Trial primary completion date: May 2023 --> May 2025 Not yet recruiting --> Recruiting
- | CCI-001 / PharmaMatrix Holdings
New P1 trial, Metastases: A Study of CCI-001 in Patients With Recurrent and/or Metastatic Solid Tumours (clinicaltrials.gov) - Apr 1, 2021
P1, N=70, Not yet recruiting, Sponsor: PharmaMatrix Holdings Ltd